Overview - Revolution Medicines is targeting RAS-addicted cancers, which are driven by RAS proteins and affect approximately 30% of human cancers[6, 8, 119] - The company is developing RAS(ON) inhibitors and RAS companion inhibitors to address this high unmet need[6, 11] RMC-6236 (RASMULTI Inhibitor) - RMC-6236 is a first-in-class RASMULTI(ON) inhibitor with potential against various RAS-addicted cancers, targeting approximately 137,000 new KRASG12X patients per year in the U S [17, 18] - Preclinical data shows robust anti-tumor activity in cancer models with common RAS variants, including KRASG12D, KRASG12V, KRASG12R, and KRASG12C[20] - In preclinical studies, RMC-6236 demonstrated a 44% Objective Response Rate (ORR) and 56% Disease Control Rate (DCR) in NSCLC models, 61% ORR and 89% DCR in PDAC models, and 53% ORR and 100% DCR in CRC models[24] RMC-6291 (KRASG12C Inhibitor) - RMC-6291 is a mutant-selective RAS(ON) inhibitor with best-in-class potential for KRASG12C cancers, addressing approximately 29,000 new patients per year in the U S [33, 34] - Preclinical studies in KRASG12C NSCLC models showed a 72% ORR and 92% DCR with RMC-6291, compared to 52% ORR and 72% DCR with Adagrasib[39] - RMC-6291 also demonstrated anti-tumor immunity in vivo and strong additivity with checkpoint inhibitors[48] RMC-9805 (KRASG12D Inhibitor) - RMC-9805 is a first-in-class mutant-selective RAS(ON) inhibitor for KRASG12D cancers, targeting approximately 55,000 new patients per year in the U S [51, 52] - Preclinical data shows rapid, deep, and sustained regressions in KRASG12D lung, pancreatic, and colorectal cancers[53] - In preclinical studies, RMC-9805 demonstrated a 64% ORR and 68% DCR across various KRASG12D cancer models[61] RMC-8839 (KRASG13C Inhibitor) - RMC-8839 is a first-in-class mutant-selective RAS(ON) inhibitor for KRASG13C cancers, addressing approximately 3,000 new patients per year in the U S [64, 65] - Preclinical data shows rapid, deep, and sustained regressions in KRASG13C lung cancers[66] Financial Status - As of September 30, 2022, Revolution Medicines had $655 million in cash, cash equivalents, and marketable securities, projecting funding for planned operations through 2024[116] - The company anticipates a 2022 GAAP net loss of $260 million to $280 million, including approximately $30 million to $35 million in non-cash stock-based compensation expense[116]

On Target to Outsmart Cancer November 6, 2024 © 2024 Revolution Medicines, Inc. Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to manage existing collaborations and esta ...

Core Insights - Revolution Medicines and Summit Therapeutics have entered a clinical collaboration to evaluate the safety and efficacy of RAS(ON) inhibitors in combination with Summit's ivonescimab across multiple solid tumor types [1][2][3] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805) [4] - Summit Therapeutics is a biopharmaceutical oncology company dedicated to developing patient-friendly therapies aimed at improving quality of life and addressing unmet medical needs [5][6] Clinical Collaboration Details - The collaboration will assess combinations of RAS(ON) inhibitors with ivonescimab in three priority tumor types: RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC) [2] - Under the agreement, Summit will provide ivonescimab for clinical research, while Revolution Medicines will act as the study sponsor, with both companies retaining commercial rights to their respective compounds [2] Drug Development Insights - Initial evidence suggests that daraxonrasib and elironrasib can provide additive antitumor activity when combined with a PD-1 antibody in first-line treatment for RAS mutant non-small cell lung cancer [2] - The collaboration aims to explore the therapeutic potential of combining investigational drugs from Revolution's RAS(ON) inhibitor portfolio with Summit's advanced PD-1 / VEGF bispecific inhibitor [3]

Summary of Revolution Medicines Conference Call Company Overview - **Company**: Revolution Medicines - **Industry**: Biotechnology, specifically focused on targeted therapies for RAS addicted cancers Key Points and Arguments 1. **Partnership with Royalty Pharma**: Revolution Medicines announced a significant partnership with Royalty Pharma, which will provide up to $2 billion in committed capital to support the development of their late-stage pipeline of RAS inhibitors while allowing the company to retain full control of its assets [4][5][6] 2. **Financial Position**: As of March 30, 2025, Revolution Medicines reported $2.1 billion in cash and investments. The partnership with Royalty Pharma adds an additional $2 billion in capital, structured to avoid equity dilution for shareholders [5][6][30] 3. **Funding Structure**: The funding arrangement includes approximately two-thirds in the form of a synthetic royalty and the remainder as corporate debt. The synthetic royalty will provide $1.25 billion in exchange for tiered royalties on future sales of diraxonrasib, with specific milestones triggering access to funds [24][25][29] 4. **Clinical Development Plans**: The company is committed to advancing its pipeline, which includes diraxonrasib, a multi-selective RAS inhibitor, and other candidates targeting various RAS mutations. The focus remains on executing robust global Phase III clinical trials [10][18][19] 5. **Market Focus**: The U.S. market is a strategic priority for Revolution Medicines, with plans to establish a standalone U.S.-based commercial capability. The company also aims to expand into select international markets, including Europe and Japan, using a phased approach [20][21][22] 6. **Regulatory Designation**: Diraxonrasib has received breakthrough therapy designation from the FDA for previously treated metastatic pancreatic cancer with KRAS G12 mutations, indicating strong potential for market impact [33] 7. **Strategic Independence**: Revolution Medicines aims to maintain strategic and execution control over its global commercialization efforts, which is expected to enhance decision-making speed and align strategic priorities without the complications of partnerships [45][46] 8. **Clinical Pipeline**: The company is focused on developing a portfolio of RAS inhibitors, including diraxonrasib, elyronrasib, and zoldonrasib, targeting various cancer types such as pancreatic cancer, non-small cell lung cancer, and colorectal cancer [18][19][73] Additional Important Content 1. **Market Opportunity**: The company recognizes the significant unmet medical need in treating RAS addicted cancers, particularly pancreatic cancer, which has a high prevalence of RAS mutations [19] 2. **Financial Guidance**: Revolution Medicines has withdrawn its previous guidance on expected GAAP net loss for 2025 as it evaluates the accounting treatment of the new funding arrangement [31][94] 3. **Talent Acquisition**: The company is actively growing its organization to support its ambitious clinical and commercialization plans, attracting experienced professionals in the biotechnology field [10][96] 4. **Long-term Vision**: Revolution Medicines is committed to creating an industry-leading targeted medicines franchise for patients with RAS addicted cancers, emphasizing the importance of innovative drug mechanisms and clinical data [33][34] This summary encapsulates the critical insights and strategic direction of Revolution Medicines as discussed in the conference call, highlighting their financial strategies, clinical development plans, and market focus.

Core Insights - Revolution Medicines has partnered with Royalty Pharma to secure $2 billion in flexible funding aimed at supporting its global development and commercialization strategy for RAS-addicted cancers [1][2][5] - The funding agreement allows Revolution Medicines to maintain full control over the development and commercialization of its RAS(ON) inhibitor portfolio, which is crucial for establishing new standards of care [1][2][3] Funding Agreement Overview - The funding consists of up to $1.25 billion in synthetic royalty monetization on sales of daraxonrasib and up to $750 million in corporate debt [3][5] - The agreement provides significant flexibility, with $1.25 billion available at the company's discretion, contingent on achieving specific milestones [3][5] Synthetic Royalty Details - Royalty Pharma will provide up to $1.25 billion in exchange for tiered royalties over 15 years on worldwide annual net sales of daraxonrasib, with decreasing royalty rates based on sales volume [6][13] - The first two tranches of $250 million each are payable before FDA approval, with the first tranche already received [6][13] Debt Facility Details - The debt facility consists of up to $750 million in senior secured term loans, with the first tranche available after FDA approval of daraxonrasib for metastatic pancreatic ductal adenocarcinoma [13] - The interest rate for the debt is based on the 3-month Standard Overnight Financing Rate (SOFR) plus 5.75%, with a SOFR floor of 3.50% [13] Cash Runway Update - Following the funding agreement, the company has removed its cash runway end date guidance, indicating improved financial stability [9] Company Background - Revolution Medicines is focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes multiple RAS(ON) inhibitors currently in clinical development [12]

Core Insights - Revolution Medicines, Inc. has received Breakthrough Therapy Designation from the FDA for daraxonrasib, a multi-selective inhibitor targeting RAS mutations in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) patients with KRAS G12 mutations [1][3][8] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, with a pipeline that includes RAS(ON) inhibitors such as daraxonrasib, elironrasib, and zoldonrasib [9] Clinical Development - The Breakthrough Therapy Designation is based on positive results from the Phase 1 RMC-6236-001 clinical trial of daraxonrasib in metastatic PDAC patients [2][8] - The company is currently enrolling patients in the RASolute 302 Phase 3 registrational study, which aims to evaluate daraxonrasib's efficacy in a core population with RAS mutations at position 12 and an expanded population with other RAS mutations [4][8] Market Context - Pancreatic cancer is one of the most lethal cancers, with approximately 60,000 new diagnoses and 50,000 deaths expected in the U.S. in 2024 [5] - PDAC accounts for about 92% of all pancreatic cancer cases, with over 90% of patients having tumors with RAS mutations, highlighting the significant unmet medical need for effective treatments [6][5]

Core Insights - Revolution Medicines (NASDAQ: RVMD) has shown promising developments, particularly highlighted during the ASCO GI meeting in January [1] Company Analysis - The company is focused on the biotechnology sector, with a strong emphasis on clinical trials and scientific research [1] - The analyst has a PhD in biochemistry and extensive experience in analyzing biotech companies, indicating a deep understanding of the industry [1] Industry Context - The biotechnology industry is characterized by its complexities and the necessity for thorough due diligence to avoid investment pitfalls [1]

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in patients with previously treated, locally advanced or metastatic ...

Revolution Medicines (RVMD) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Ryan Asay - SVP & Corporate AffairsMark Goldsmith - CEO, President & ChairmanSteve Kelsey - President of Research & DevelopmentWei Lin - Chief Medical OfficerJack Anders - Chief Financial OfficerNone - ExecutiveJonathan Chang - Senior Managing DirectorClara Dong - Vice President - Biotechnology Equity Research Conference Call Participants Michael Schmidt - Senior Managing Director & Equity Research Analyst - Biot ...

Financial Data and Key Metrics Changes - The company ended Q1 2025 with $2.1 billion in cash and investments, projected to fund operations into the second half of 2027 [42] - R&D expenses for Q1 2025 were $205.7 million, up from $118 million in Q1 2024, primarily due to increased clinical trial and manufacturing expenses [42] - G&A expenses rose to $35 million in Q1 2025 from $22.8 million in Q1 2024, driven by personnel-related expenses and stock-based compensation [43] - The net loss for Q1 2025 was $213.4 million, compared to $116 million in Q1 2024, attributed to higher operating expenses [43] - The company reiterated its 2025 financial guidance, expecting a full-year GAAP net loss between $840 million and $900 million [43] Business Line Data and Key Metrics Changes - The company is advancing three clinical-stage RasOn inhibitors: doraxonrasib, elieronrasib, and zoldonrasib, focusing on RAS mutant cancers [6][10] - Doraxonrasib is currently in two Phase III trials, with significant progress in pancreatic cancer and non-small cell lung cancer [45][46] - The ongoing RESOLVE-301 study is randomizing approximately 420 patients to evaluate doraxonrasib monotherapy versus docetaxel in previously treated non-small cell lung cancer [19] Market Data and Key Metrics Changes - Approximately 30% of non-small cell lung cancer patients harbor a RAS mutation, with no full regulatory approvals for RAS inhibitors in this space [10] - The segmentation of RAS mutant non-small cell lung cancer is expected to continue as more selective inhibitors advance through clinical development [11] Company Strategy and Development Direction - The company aims to revolutionize treatment for RAS addicted cancers through innovative targeted medicines, focusing on both single-agent and combination strategies [5][6] - A key focus for 2025 is executing registrational studies for doraxonrasib in both pancreatic and non-small cell lung cancers [45] - The company plans to initiate additional Phase III studies for doraxonrasib in pancreatic cancer in the second half of 2025 [7][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing enrollment for the RASLUT-302 trial and the RESOLVE-301 trial, expecting substantial completion this year [45][46] - The company is also advancing its earlier-stage pipeline, including a G12V mutant selective RasOn inhibitor, with plans for a Phase I study next year [48] - The management emphasized the importance of building commercialization capabilities in the U.S. and ensuring patient access to doraxonrasib globally [49][50] Other Important Information - The company has appointed Anthony Mancini as Chief Global Commercialization Officer to oversee commercialization strategy and operations [49] - The company is focused on establishing a leading portfolio of RasOn inhibitors as therapies for RAS mutant non-small cell lung cancer across all mutations and lines of therapy [11][12] Q&A Session Summary Question: Can you comment on the confidence and tolerability of the triplet combination for first-line non-small cell lung cancer? - Management expressed optimism based on the profile seen so far, noting no new safety signals have emerged [56][57] Question: What is the average follow-up in the cohorts, and what data is needed to declare Phase III intent for combinations? - Management indicated that follow-up data is available from previous presentations, and they believe they have sufficient data to proceed with the non-G12C program [60][62] Question: What is the company's strategy for commercial opportunities outside the U.S.? - Management discussed the importance of a comprehensive commercial strategy and potential partnerships, with plans to meet with the FDA to discuss pivotal trial designs [92]